Hasil Pencarian - Jeng-Sen Tseng

  • Menampilkan 1 - 18 hasil dari 18
Perbaiki Hasil
  1. 1
    Pulmonary aspergillosis in an immunocompetent patient

    Pulmonary aspergillosis in an immunocompetent patient oleh Wei-Lun Chien, Jeng-Sen Tseng

    Diterbitkan 2013-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Pulmonary aspergillosis in an immunocompetent patient

    Pulmonary aspergillosis in an immunocompetent patient oleh Wei-Lun Chien, Jeng-Sen Tseng

    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Comprehensive Analysis and Risk Identification of Pulmonary Cryptococcosis in Non-HIV Patients

    Comprehensive Analysis and Risk Identification of Pulmonary Cryptococcosis in Non-HIV Patients oleh Chun Lin, Tsung-Ying Yang, Ming-Cheng Chan, Kuo-Hsuan Hsu, Yen-Hsiang Huang, Jeng-Sen Tseng

    Diterbitkan 2021-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Benefits of NGS in Advanced Lung Adenocarcinoma Vary by Populations and Timing of Examination

    Benefits of NGS in Advanced Lung Adenocarcinoma Vary by Populations and Timing of Examination oleh Po-Hsin Lee, Wei-Fan Ou, Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng-Sen Tseng, Gee-Chen Chang, Tsung-Ying Yang

    Diterbitkan 2024-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Attenuation of PI3K-Akt-mTOR Pathway to Reduce Cancer Stemness on Chemoresistant Lung Cancer Cells by Shikonin and Synergy with BEZ235 Inhibitor

    Attenuation of PI3K-Akt-mTOR Pathway to Reduce Cancer Stemness on Chemoresistant Lung Cancer Cells by Shikonin and Synergy with BEZ235 Inhibitor oleh Yen-Hsiang Huang, Ling-Yen Chiu, Jeng-Sen Tseng, Kuo-Hsuan Hsu, Chang-Han Chen, Gwo-Tarng Sheu, Tsung-Ying Yang

    Diterbitkan 2024-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Adjuvant chemotherapy compared with observation in patients with T2aN0 stage IB lung adenocarcinoma

    Adjuvant chemotherapy compared with observation in patients with T2aN0 stage IB lung adenocarcinoma oleh Po-Hsin Lee, Po-Hsin Lee, Po-Hsin Lee, Po-Hsin Lee, Chun-Ju Chiang, Chun-Ju Chiang, Jeng-Sen Tseng, Jeng-Sen Tseng, Jeng-Sen Tseng, Jeng-Sen Tseng, Zhe-Rong Zheng, Zhe-Rong Zheng, Zhe-Rong Zheng, Kun-Chieh Chen, Kun-Chieh Chen, Cheng-Hsiang Chu, Cheng-Hsiang Chu, Yen-Hsiang Huang, Yen-Hsiang Huang, Yen-Hsiang Huang, Kuo-Hsuan Hsu, Wen-Chung Lee, Wen-Chung Lee, Tsung-Ying Yang, Tsung-Ying Yang, Tsang-Wu Liu, Jiun-Yi Hsia, Jiun-Yi Hsia, Gee-Chen Chang, Gee-Chen Chang, Gee-Chen Chang, Gee-Chen Chang

    Diterbitkan 2023-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced <i>EGFR</i>-Mutant Lung Adenocarcinoma

    Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced <i>EGFR</i>-Mutant Lung Adenocarcinoma oleh Po-Hsin Lee, Yen-Hsiang Huang, Ho Lin, Kuo-Hsuan Hsu, Kun-Chieh Chen, Jeng-Sen Tseng, Gee-Chen Chang, Tsung-Ying Yang

    Diterbitkan 2022-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma.

    Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma. oleh Kang-Yi Su, Jeng-Sen Tseng, Keng-Mao Liao, Tsung-Ying Yang, Kun-Chieh Chen, Kuo-Hsuan Hsu, Pan-Chyr Yang, Sung-Liang Yu, Gee-Chen Chang

    Diterbitkan 2018-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors

    Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors oleh Po-Hsin Lee, Tsung-Ying Yang, Kun-Chieh Chen, Yen-Hsiang Huang, Jeng-Sen Tseng, Kuo-Hsuan Hsu, Yu-Chen Wu, Ko-Jiunn Liu, Gee-Chen Chang

    Diterbitkan 2021-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M

    Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M oleh Yen-Hsiang Huang, Jeng-Sen Tseng, Kuo-Hsuan Hsu, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J. W. Chen, Tsung-Ying Yang, Gee-Chen Chang

    Diterbitkan 2021-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M

    The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M oleh Yen-Hsiang Huang, Jeng-Sen Tseng, Kuo-Hsuan Hsu, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J. W. Chen, Tsung-Ying Yang, Gee-Chen Chang

    Diterbitkan 2021-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients

    PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients oleh Kuo-Hsuan Hsu, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J. W. Chen, Yen-Hsiang Huang, Gee-Chen Chang

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Various impacts of driver mutations on the PD-L1 expression of NSCLC.

    Various impacts of driver mutations on the PD-L1 expression of NSCLC. oleh Cheng-Hsiang Chu, Yen-Hsiang Huang, Po-Hsin Lee, Kuo-Hsuan Hsu, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeng-Sen Tseng, Tsung-Ying Yang, Gee-Chen Chang

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Primary tumor consolidative therapy improves the outcomes of patients with advanced -mutant lung adenocarcinoma treated with first-line osimertinib

    Primary tumor consolidative therapy improves the outcomes of patients with advanced -mutant lung adenocarcinoma treated with first-line osimertinib oleh Jia-Jun Wu, Jeng-Sen Tseng, Zhe-Rong Zheng, Cheng-Hsiang Chu, Kun-Chieh Chen, Mong-Wei Lin, Yen-Hsiang Huang, Kuo-Hsuan Hsu, Tsung-Ying Yang, Sung-Liang Yu, Jin-Shing Chen, Chao-Chi Ho, Gee-Chen Chang

    Diterbitkan 2024-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation

    Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation oleh Jia-Jun Wu, MD, Po-Hsin Lee, MD, Zhe-Rong Zheng, MD, Yen-Hsiang Huang, MD, Jeng-Sen Tseng, MD, PhD, Kuo-Hsuan Hsu, MD, Tsung-Ying Yang, MD, PhD, Sung-Liang Yu, PhD, Kun-Chieh Chen, MD, PhD, Gee-Chen Chang, MD, PhD

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma.

    Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma. oleh Jeng-Sen Tseng, Chih-Liang Wang, Ming-Shyan Huang, Chung-Yu Chen, Cheng-Yu Chang, Tsung-Ying Yang, Chi-Ren Tsai, Kun-Chieh Chen, Kuo-Hsuan Hsu, Meen-Hsin Tsai, Sung-Liang Yu, Kang-Yi Su, Chih-Wei Wu, Cheng-Ta Yang, Yuh-Min Chen, Gee-Chen Chang

    Diterbitkan 2014-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study

    The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicente... oleh Yen-Hsiang Huang, Jen-Yu Hung, How-Wen Ko, Po-Lan Su, Chun-Liang Lai, Huang-Chih Chang, Te-Chun Hsia, Sheng-Hao Lin, Kuan-Li Wu, Cheng-Ta Yang, Wu-Chou Su, Yi-Chun Chu, Chin-Chou Wang, Wei-Yu Liao, Yen-Ting Lin, Ching-Hsiung Lin, Meng-Chih Lin, Kuo-Hsuan Hsu, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Mei-Hsuan Lee, Sung-Liang Yu, Chao-Chi Ho, Gee-Chen Chang

    Diterbitkan 2021-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in Taiwan.

    Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in Taiwan. oleh Kuo-Hsuan Hsu, Chao-Chi Ho, Te-Chun Hsia, Jeng-Sen Tseng, Kang-Yi Su, Ming-Fang Wu, Kuo-Liang Chiu, Tsung-Ying Yang, Kun-Chieh Chen, Hean Ooi, Tzu-Chin Wu, Hung-Jen Chen, Hsuan-Yu Chen, Chi-Sheng Chang, Chung-Ping Hsu, Jiun-Yi Hsia, Cheng-Yen Chuang, Chin-Hung Lin, Jeremy J W Chen, Kuan-Yu Chen, Wei-Yu Liao, Jin-Yuan Shih, Sung-Liang Yu, Chong-Jen Yu, Pan-Chyr Yang, Gee-Chen Chang

    Diterbitkan 2015-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: